Company profile · Sponsor
Recordati
Recordati Ireland
- Pipeline
- 4
- Drugs
- 0
- Patents
- 0
Quick answer
Recordati (EEC3FDD) is a pharma company. headquartered in IE. listed on EMA. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 0 patents to this profile..
Company facts
Pipeline (4)
Search pipeline →-
A double-blind, randomized, placebo-controlled, dose-finding phase II study to assess the efficacy and safety of pasireotide s.c. in patients with Post-Bariatric Hypoglycaemia
Recordati
Post-Bariatric Hypoglycaemia
1 trial -
Isturisa 1 mg film-coated tablets, Isturisa 5 mg film-coated tablets, Isturisa 10 mg film-coated tablets
Recordati
Cushing's disease
1 trial -
A study to find out whether the medication pasireotide is absorbed and processed the same way when given under the skin using either a reusable pen or a syringe in healthy subjects
Recordati
Post-bariatric hypoglycaemia
1 trial -
Relative bioavailability and safety study of pasireotide after a single-dose subcutaneous administration in the arm or in the thigh compared to in the abdomen using a ServoPen in healthy subjects.
Recordati
Post-bariatric hypoglycaemia
1 trial
Frequently asked questions
What is Recordati?
Recordati (EEC3FDD) is a pharma company. headquartered in IE. listed on EMA. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 0 patents to this profile..
What pipeline programs does Recordati sponsor?
We track 4 ClinicalTrials.gov-linked programs for Recordati, including A double-blind, randomized, placebo-controlled, dose-finding phase II study to assess the efficacy and safety of pasireotide s.c. in patients with Post-Bariatric Hypoglycaemia and 3 more. Open each program for phase, modality, NCT IDs, and indication details.
Where does Recordati company data come from?
Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.